These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12406430)

  • 1. Ankylosing spondylitis and current disease-controlling agents: do they work?
    Maksymowych WP; Breban M; Braun J
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):619-30. PubMed ID: 12406430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
    Van den Bosch F; De Keyser F; Mielants H; Veys EM
    Arthritis Res Ther; 2005; 7(3):121-3. PubMed ID: 15899063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
    Anderson JJ; Baron G; van der Heijde D; Felson DT; Dougados M
    Arthritis Rheum; 2001 Aug; 44(8):1876-86. PubMed ID: 11508441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?
    Ward MM
    Arthritis Rheum; 2005 Jun; 52(6):1634-6. PubMed ID: 15934065
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment and treatment of ankylosing spondylitis: current status and future directions.
    Zochling J
    Curr Opin Rheumatol; 2008 Jul; 20(4):398-403. PubMed ID: 18525351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis].
    Madsen OR; Egsmose C
    Ugeskr Laeger; 2009 Aug; 171(33):2268-72. PubMed ID: 19732504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample sizes estimated in clinical trials using either a composite index (ASAS response criteria) or single outcome variables in ankylosing spondylitis.
    Auleley GR; Dougados M; Baron G
    Arthritis Rheum; 2002 Jun; 46(6):1693-4. PubMed ID: 12115205
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodology issues in the evaluation of NSAID in inflammatory rheumatic diseases.
    Lequesne M
    J Rheumatol Suppl; 1990 Feb; 20():25-8. PubMed ID: 2182853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for ankylosing spondylitis: new treatment modalities.
    Braun J; Breban M; Maksymowych WP
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):631-51. PubMed ID: 12406431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bechterew disease--a consensus on diagnosis and treatment].
    Dagfinrud H; Heiberg MS; Bakland G; Skomsvoll J; Kvien TK
    Tidsskr Nor Laegeforen; 2007 Dec; 127(24):3209-12. PubMed ID: 18084362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ankylosing spondylitis--the current situation and new therapeutic options].
    Zlnay D; Zlnay M; Rovenský J
    Vnitr Lek; 2006; 52(7-8):730-5. PubMed ID: 16967616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.